| CAS NO: | 274693-27-5 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 100mg | 电议 |
| 500mg | 电议 |
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 522.57 |
| Cas No. | 274693-27-5 |
| Formula | C23H28F2N6O4S |
| Solubility | ≥26.15 mg/mL in DMSO; insoluble in H2O; ≥20.4 mg/mL in EtOH |
| Chemical Name | (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Canonical SMILES | CCCSC1=NC2=C(C(=N1)NC3CC3C4=CC(=C(C=C4)F)F)N=NN2C5CC(C(C5O)O)OCCO |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
Ticagrelor是一种新的P2Y12受体拮抗剂[1].
Ticagrelor可拮抗P2Y12受体,抑制血小板上ADP的血栓功能.Ticagrelor在体外可完全抑制血小板凝集.此外,Ticagrelor对人类血小板凝集有剂量依赖的抑制功能.除此之外,Ticagrelor也是一种可口服的\活跃的和可逆的结合拮抗剂.不像其他抑制剂,Ticagrelor可抑制P2Y12受体而不发生代谢转化.另外,Ticagrelor是第一种噻吩并吡啶类抗血小板制剂,且主要由CYP3A4和CYP2C19代谢[1][2].
参考文献：
[1] Zhou D1, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011 Apr;39(4):703-10.
[2] Li Y1, Landqvist C, Grimm SW. Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets. Drug Metab Dispos. 2011 Sep;39(9):1555-67. doi: 10.1124/dmd.111.039669. Epub 2011 Jun 13.
m.cnreagent.com